Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Heart Disease Health Center

Font Size

New Plavix Findings Fuel Debate on Platelet Testing

Doubling Plavix Dose Doesn't Help Certain High-Risk People
WebMD Health News
Reviewed by Laura J. Martin, MD

Nov. 17, 2010 (Chicago) -- Doubling the dose of the anticlotting drug Plavix does not reduce heart attacks or deaths in certain high-risk people, a study shows.

The study participants were determined to be at high risk of cardiovascular complications after undergoing a test showing that their blood was still prone to clotting despite taking the anticlotting medication. Clots can lodge in an artery, causing a heart attack or stroke.

Whether the test, called platelet reactivity testing, should be given to people taking Plavix has been the subject of much debate.

"We're not set up to recommend it at this time," says Mariell Jessup, MD, medical director of the Penn Heart and Vascular Center at the University of Pennsylvania.

High-Dose Plavix Doesn't Cut Cardiovascular Events

Some people are genetically predisposed to be poor metabolizers of Plavix, and they have higher rates of heart attacks, strokes, and death.

To compensate for this poor response, doctors often increase the dose of Plavix in these patients. But the strategy of using the platelet reactivity test to guide treatment with Plavix had not been evaluated in a large clinical trial until now.

Matthew Price, MD, of the Scripps Clinic in La Jolla, Calif., presented the findings at the American Heart Association annual meeting.

Using the platelet reactivity test, Price and colleagues identified more than 2,200 patients who were poor metabolizers of Plavix after taking the standard Plavix dose 12 to 24 hours after angioplasty and stenting, procedures that open blocked heart arteries.

The patients were then given either a high or a standard dose of Plavix for six months.

After six months, the rate of death due to cardiovascular disease, heart attack, or developing a blood clot inside the stent was 2.3% in both groups.

The study was funded by Accumetrics Inc., which makes the platelet reactivity test used in the study.

Platelet Testing

But platelet reactivity testing is not dead, doctors tell WebMD.

Other strategies may prove helpful for people whose test shows high platelet activity, they say.

It could be an even higher dose of Plavix is needed, Jessup says.

Today on WebMD

x-ray of human heart
A visual guide.
atrial fibrillation
Symptoms and causes.
heart rate graph
10 things to never do.
heart rate
Get the facts.
empty football helmet
red wine
eating blueberries
Simple Steps to Lower Cholesterol
Inside A Heart Attack
Omega 3 Sources
Salt Shockers
lowering blood pressure